United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) EVP Paul Mahon sold 8,300 shares of the business’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $482.03, for a total value of $4,000,849.00. Following the completion of the transaction, the executive vice president owned 45,172 shares in the company, valued at $21,774,259.16. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
United Therapeutics Trading Down 0.5%
Shares of UTHR opened at $487.61 on Friday. The business’s 50 day moving average is $525.95 and its 200 day moving average is $539.55. United Therapeutics Corporation has a 12-month low of $375.61 and a 12-month high of $609.35. The company has a market capitalization of $20.91 billion, a PE ratio of 17.45, a price-to-earnings-growth ratio of 2.45 and a beta of 0.56.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the prior year, the company posted $6.41 EPS. Equities research analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current year.
Wall Street Analyst Weigh In
Read Our Latest Analysis on UTHR
United Therapeutics News Summary
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: The FDA accepted United Therapeutics’ supplemental new drug application for Tyvaso in idiopathic pulmonary fibrosis (IPF). The application is supported by Phase 3 TETON data showing improved lung function and reduced clinical worsening. FDA review is expected to conclude in April 2027, and approval could materially expand Tyvaso’s addressable market. FDA Accepts UTHR’s sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
- Neutral Sentiment: Analysts remain broadly constructive, with a consensus “Moderate Buy” rating and an average price target near $646. However, several firms have recently lowered their targets, indicating that optimism about UTHR’s pipeline and valuation is tempered by execution and growth concerns. Analyst Sentiment on United Therapeutics
- Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $4.69 million, while EVP Paul Mahon sold 8,300 shares for about $4.00 million. Mahon’s sale reduced his holdings by 15.52%, and the transactions may be weighing on investor sentiment, even though the CEO’s sale was disclosed through an SEC filing and may have been prearranged. United Therapeutics Insider Selling
- Negative Sentiment: The latest quarterly results exceeded EPS expectations, but revenue of $783.3 million fell short of the $804.7 million consensus estimate and declined 1.9% year over year. The revenue weakness, combined with competition affecting pulmonary hypertension therapies, helps explain why investors remain cautious after earnings. United Therapeutics Earnings Performance
Institutional Trading of United Therapeutics
Hedge funds have recently made changes to their positions in the business. Arjuna Capital grew its position in United Therapeutics by 2.8% in the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after acquiring an additional 18 shares in the last quarter. Sage Rhino Capital LLC increased its position in United Therapeutics by 5.1% during the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after acquiring an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC raised its stake in shares of United Therapeutics by 5.4% in the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 24 shares during the period. Meeder Advisory Services Inc. raised its stake in shares of United Therapeutics by 4.1% in the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after acquiring an additional 26 shares during the period. Finally, Independent Advisor Alliance lifted its holdings in shares of United Therapeutics by 3.3% in the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after acquiring an additional 27 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.
About United Therapeutics
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
- Five stocks we like better than United Therapeutics
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
